Although small numbers of patients with ALK fusion NSCLC were included in the randomized phase 3 CheckMate 057 and KEYNOTE-010 studies comparing ICI versus docetaxel in previously treated NSCLC patient population, the outcomes in this specific population were not reported (35, 36). Here, ALK is linked to non-small cell lung carcinoma.